postherpetic trigeminal neuralgia
Conditions
Interventions
Experimental group:Oral gabapentine combined with PRP injection
Control group:Oral gabapentin therapy
Sponsors
Chengdu Fifth People's Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with post-herpetic trigeminal neuralgia who have been clinically confirmed and whose pain has lasted for at least 1 month. 2. Aged 45-75 years.
Exclusion criteria
Exclusion criteria: 1. All other diseases that may cause facial area pain (primary trigeminal neuralgia, intracranial space occupying, glossopharyngeal neuralgia, temporomandibular arthritis, etc.). 2. Postherpetic neuralgia of other cranial nerves (oculomotor nerve palsy of herpes zoster, herpes meningitis, etc.). 3. Patients with severe cardiovascular and cerebrovascular diseases and respiratory diseases combined with serious other systemic diseases cannot complete the treatment. 4. Patients with a history of allergy to related therapeutic drugs. 5. Patients with abnormal coagulation function and those who take anticoagulant and anticoagulant tablets within a week. 6. Patients with diabetes and mental illness, recent use of antipsychotics, alcohol or drug abuse, and language and communication disorders. 7. Puncture site infection. 8. Ultrasound showed unclear anatomical structure. 9. Critical thrombocytopenia, hemorrhagic diseases (allergic purpura, hemophilia, essential thrombocytopenia purpura, etc.). 10. Leukemia and septicaemia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NRS Numerical Pain Scale Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative complication rate;Postoperative pain recurrence rate;Postoperative pain relief; | — |
Countries
China
Contacts
Public ContactYang Tao
Chengdu Fifth People's Hospital
Outcome results
None listed